Additionally, in ER+ breast cancer cells, EZH2 has been found to noncanonically interact with estrogen receptor α (ERα) and β-catenin, forming a ternary complex that binds to MYC promoter at the LEF/TCF-binding sites, thereby inducing its transcription [77]. Here, EZH2 is linked to breast carcinoma.